Literature DB >> 27181992

Maintenance of Mycobacterium tuberculosis-specific T cell responses in End Stage Renal Disease (ESRD) and implications for diagnostic efficacy.

Jennifer A Juno1, Jillian L M Waruk2, Christine Mesa2, Carmen Lopez3, Joe Bueti4, T Blake Ball5, Sandra A Kiazyk5.   

Abstract

End-stage renal disease (ESRD) patients exhibit elevated risk of tuberculosis (TB) reactivation, but current diagnostics, including the interferon gamma release assay (IGRA), exhibit poor sensitivity in ESRD. We tested 80 ESRD patients and found an 18.75% prevalence of IGRA positivity. A subset of patients was assessed for Mtb-specific expression of 44 cytokines/chemokines, and CD4+ T cell phenotype and function. Similar to non-ESRD IGRA+ individuals, Mtb-specific IFNγ, IL-1RA, IP-10, MCP-3 and IL-2 responses were identified in the ESRD IGRA+ group. 27% of the ESRD IGRA- group exhibited MCP-3 or IL-2 Mtb-specific responses, which may identify cases of latent TB infection in ESRD. Stimulation of PBMC with PPD demonstrated similar CD4+ T cell production of IFNγ, TNFα and GM-CSF by ESRD patients. The reported low sensitivity of the IGRA in ESRD cohorts is therefore unlikely to be due to poor T cell cytokine secretion, and may instead reflect defects in antigen presentation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; ESRD; IGRA; MCP-3; TB

Mesh:

Substances:

Year:  2016        PMID: 27181992     DOI: 10.1016/j.clim.2016.05.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  4 in total

Review 1.  An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.

Authors:  Milla R McLean; Lenette L Lu; Stephen J Kent; Amy W Chung
Journal:  Front Immunol       Date:  2019-12-09       Impact factor: 7.561

2.  Serological and cellular inflammatory signatures in end-stage kidney disease and latent tuberculosis.

Authors:  Milla R McLean; Kathleen M Wragg; Ester Lopez; Sandra A Kiazyk; Terry Blake Ball; Joe Bueti; Stephen J Kent; Jennifer A Juno; Amy W Chung
Journal:  Clin Transl Immunology       Date:  2021-11-05

Review 3.  CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease.

Authors:  Ting-Ting Chang; Ching Chen; Jaw-Wen Chen
Journal:  Cardiovasc Diabetol       Date:  2022-09-15       Impact factor: 8.949

4.  Mucosal-Associated Invariant T Cells Are Depleted and Exhibit Altered Chemokine Receptor Expression and Elevated Granulocyte Macrophage-Colony Stimulating Factor Production During End-Stage Renal Disease.

Authors:  Jennifer A Juno; Jillian L M Waruk; Kathleen M Wragg; Christine Mesa; Carmen Lopez; Joe Bueti; Stephen J Kent; T Blake Ball; Sandra A Kiazyk
Journal:  Front Immunol       Date:  2018-05-17       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.